PapersPMID:31694759
Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4-/-: A double-blind, randomized, placebo-controlled crossover trial.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →“Changes in ADL scores were not significantly different between the MCT and placebo interventions (p > 0.05).”
- Study
- crossover
- Duration
- 4 weeks
- Dose studied
- MCT jelly by mouth three times daily, total daily fat dose 17.3 g MCT, 30 days per phase
- Population
- Adults with mild to moderate Alzheimer's disease, APOE4-/- subjects who completed the study analysed; MCT jelly versus canola-oil placebo jelly in a double-blind crossover
Study record
- Design
- crossover trial
- Species
- human
- Population
- patients with mild to moderate Alzheimer's disease (APOE4-/- analysed); abstract-only record
- Participants
- 53
- Comparator
- placebo
- Duration
- 30 days
- Endpoints measured
- 13